Zepbound

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

News

Basketball great Shaq fronts Lilly sleep apnoea campaign

Eli Lilly has recruited basketball legend Shaquille O'Neal to promote a sleep apnoea awareness campaign and make the case for treatment with Zepbound.

News

France 'first EU country to cover obesity drugs'

France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.

News

Lilly UK recruits ex-England cricketer as obesity champion

Lilly UK's obesity champion Ashley Giles, who won the Ashes with England in 2005, is urging people struggling with their weight to ask for help.

Lilly fleshes out triple G data in diabetes and obesity

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Basketball great Shaq fronts Lilly sleep apnoea campaign

France 'first EU country to cover obesity drugs'

Lilly UK recruits ex-England cricketer as obesity champion

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

Zepbound

Editor's Picks